SMARCA4 and cancer: Only few sporadic mutations (displaying lower significance levels) were able to specifically inhibit ARID1B function (effect on cancer cell proliferation in absence of destabilization), likely due to extensive cooperative binding within the complex impeding the disruption of BRG1 PPI with a single point mutation.